Navigation Links
GenVec Reports Inducement Award
Date:5/25/2012

GAITHERSBURG, Md., May 25, 2012 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) announced today that on May 23, 2012 it granted an option to purchase shares of its common stock to Cynthia Collins, its newly appointed President and Chief Executive Officer.  The option grant was approved by the Compensation Committee of GenVec's Board of Directors and the Board of Directors, and was made as an inducement material to Ms. Collins's acceptance of employment with GenVec in accordance with NASDAQ Listing Rule 5635(c)(4).

The option allows for the purchase of up to 250,000 shares of GenVec's common stock at an exercise price per share equal to $2.54, the closing price of the Company's common stock on May 23, 2012.  The option has a ten-year term and will vest and become exercisable as to one-eighth (1/8th) of the shares of common stock covered by the option on the six month anniversary of the grant date and, on the first day of each month thereafter, the option will vest and become exercisable as to an additional one-forty-eighth (1/48th) of the shares of common stock covered by the option until the option is fully exercisable.

On May 24, 2012, GenVec filed a Form 8-K regarding the appointment of Ms. Collins and related matters.  Please refer to that filing for a full description of the inducement award agreement pursuant to which the option was granted.  GenVec is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).

About GenVec
GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health, we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Retail Investor and Media Contact:     

GenVec, Inc.

Douglas J. Swirsky

(240) 632-5510

dswirsky@genvec.com

Institutional Investor Contact:

S.A. Noonan Communications

Susan A. Noonan

(212) 966-3650

susan@sanoonan.com


'/>"/>
SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GenVec Appoints Cynthia Collins as President and CEO
2. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
3. GenVec to Release Fourth Quarter and Year-End 2011 Financial Results and Conduct a Conference Call on March 15, 2012
4. Faruqi & Faruqi, LLP Announces Investigation of GenVec, Inc.
5. GenVec Extends Research Collaboration with Global Pharmaceutical Company
6. GenVec Reports Third Quarter 2011 Financial Results
7. GenVec to Release Third Quarter 2011 Financial Results and Conduct a Conference Call on November 9, 2011
8. GenVec to Present at Stifel Nicolaus 2011 Healthcare Conference
9. GenVec Reports Second Quarter 2011 Financial Results
10. GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors
11. GenVec to Host First Quarter 2011 Earnings Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... 8, 2017 MACRA replaces the outdated ... for service reimbursement. Black Book Research crowdsource-surveyed 8,845 physician ... 1.       The Market for MIPS Compliance Technology is Booming ... practices with 3 or more clinicians seek to buy ... "Given the magnitude of the changes, the hunt is ...
(Date:5/6/2017)... is Stroke Awareness Month and Omron Healthcare is reminding ... prevent a stroke: monitor and manage your blood pressure. ... undetected and uncontrolled hypertension is a leading risk factor ... personal heart health technology, recently evolved its mission to ... and is advancing a national public education effort to ...
(Date:5/4/2017)...  A recent study published in the American ... as a means of disinfection anesthesia workstations ... on anesthesia workstations. In the study, UVC disinfection ... equipment surfaces contaminated with three (3) organisms commonly ... further validates the body of literature supporting Tru-D," ...
Breaking Medicine Technology:
(Date:5/24/2017)... Massapequa Park, NY (PRWEB) , ... May 24, ... ... today announced the practice is offering holistic pediatric dentistry options for its patients ... the context of the patient’s entire physical well being, and is one of ...
(Date:5/24/2017)... ... 2017 , ... Dymedix® Diagnostics, Inc., the leading ... had completed the first phase of building a global distribution network. To date, ... (ROW) authorized dealers specializing in polysomnography accessories. The company plans to expand ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May ... since 2009, according to a Workers Compensation Research Institute (WCRI) study, a contrast ... North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical ...
(Date:5/23/2017)... ... May 23, 2017 , ... The Gallery of Cosmetic Surgery, ... pleased to announce a new treatment option called Vivace Microneedling. This treatment option ... and body through a virtually pain-free, non-surgical treatment. Vivace Microneedling combines a state-of-the-art, ...
(Date:5/23/2017)... ... May 23, 2017 , ... New patients from Charleston, SC, are now welcome ... in Mt. Pleasant, SC, with or without a referral. A full mouth reconstruction can ... missing teeth in Charleston, SC. Those who suffer from gum disease, misaligned teeth ...
Breaking Medicine News(10 mins):